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muscle strength, ultrasound could be a useful tool for assessing disease severity
and monitoring disease progression in patients with PPS.
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Introduction.– Botulinum toxin (BTX) has long been used for the treatment of
spasticity. Currently, its indications have been enlarged to the musculoskeletal
system and particularly to the management of osteo-arthropathies.
Objectives.– Describe the effects of intramuscular and intra-articular BoNT-A
in painfull arthropathies in PRM.
Method.– Literature review.
Results.– Literature data report that intramuscular injection of BoNT-A may
represent an alternative for the management of reactive periarticular muscle
contractures after joint replacement surgery or of agonist/antagonist muscle
imbalance. The literature also reports some controlled randomized studies show-
ing the higher analgesic effect of BoNT-A intra-articular injections compared to
corticosteroids in chronic knee pain,chronic shoulder joint pain due to osteoar-
ticular conditions or rheumatoid arthritis, sacroiliac joint pain and refractory
pain after knee arthroplasty.
The effects of BoNT-A intra-articular injection have been investigated in animal
models and suggests that BoNT-A slows may have a chondroprotective effect by
limiting the alterations of the cartilage structures associated to analgesic effects
through inhibition of pain mediators.
Conclusions.– BoNT-A represents an interesting therapeutic alternative both for
intramuscular injection in case of periarticular muscle contractures and for intra-
articular injection, although its intra-articular effects need to be better defined
by further studies.
Further reading
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Introduction.– Palmar hyperhidrosis is a disease that has substantial impact upon
affective, workplace and social relationships. This study aims to review the
existing evidences about the effectiveness of botulinum toxin in the treatment of
palmar hyperhidrosis and the role of iontophoresis as a drug delivery method.
Material and methods.– The expression “botulinum toxin” AND “palmar hyper-
hidrosis” AND “iontophoresis” was searched on PubMed, Cochrane and PEDro
databases. Articles were chosen for full text reading by abstract evaluation.
Results.– Botulinum toxin type A is a valid treatment option in patients with
severe sweating who have not responded to topical treatments. Benefits of using
botulinum toxin type A to inhibit palmar hyperhidrosis were documented in
several studies, however palmar injections are very painful. Previous studies
demonstrate that botulinum toxin type A can be effectively delivered to the
palms by iontophoresis.
Discussion.– Palmar hyperhidrosis can limit the patients’ quality of life.
Botulinum toxin type A iontophoresis is a non-invasive, inexpensive, safe and
effective treatment option for palmar hyperhidrosis. Considering the established
evidences, it is important to revise this unlabeled use.
Further reading
Andrade PC. Ann Bras Dermatol 2011;86:1243–6.
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Introduction.– The aim of this study was to determine and compare the efficacy
of TENS and kinesiotaping in lateral epicondylitis (LE).
Methods.– In this prospective-randomised, assessor blinded controlled trial, sev-
enty eight patients were enrolled. Patients were allocated into 4 treatment groups:
Group 1 received TENS and kinesiotaping (KT), group 2 received TENS + sham
KT, group 3 received sham TENS + KT and group 4 received sham TENS + sham
KT. TENS was applied for 10 sessions and KT for 4 times in 10 days. Outcome
measures were pain-free grip strength, pressure pain threshold, pain severity
and patient rated tennis elbow evaluation for functional status. Patients were
assessed at randomization, on day 10 and at 12th week of follow-up.
Results.– On day 10, TENS, KT combination treatments were statistically supe-
rior to sham group (P < 0.05). At week 12, all groups had statistically significant
improvements compared to pre-treatment, however there were no significant
differences among groups.
Discussion.– To our knowledge, this is the first study that evaluates TENS and
KT in LE. In this study we found that KT alone or in combination with TENS
was not superior to TENS, sham TENS or sham KT. Further research is needed
to confirm these results.
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Introduction.– Only sparse evidence exists regarding the effectiveness of oral
alendronate in the prevention of heterotopic ossification in patients with spinal
cord injury. The objective is to investigate the protective effect of oral alendronate
intake on the appearance of heterotopic ossification (HO) in patients with spinal
cord injury (SCI).
